達飛控股(01826.HK)擬出售陽光小額貸款公司10.03%股權
格隆匯1月2日丨達飛控股(01826.HK)公佈,由於楊險峯股份轉讓協議的其中一項先決條件未能於2019年12月31日前達成,故於2019年12月31日,微遠至誠與楊險峯訂立終止協議,據此,微遠至誠及楊險峯同意終止楊險峯股份轉讓協議。
此外,由於預期公司將不會於收購事項中成為目標公司大同開發區陽光小額貸款股份有限公司的單一最大股東,故董事會謹此宣佈有意出售目標公司2006萬股股份,佔10.03%股本權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.